TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy
Brief Summary: Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment ("switch") for at least three and not more than six months prior to offering an individual participation in this program. Treatment should follow local therapy guidelines and standard practice. Treatment decisions for patients participating in this study including assessments or supportive therapy during follow-up visits will also follow guidelines and remain independent of the program.


Options:
A: Arm Label: All patients; Type: N/A; Interventions: N/A
B: Arm Label: Vitamin D3 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Vitamin D3 600 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 4000 IU | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 600 IU
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.
Brief Summary: COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: azithromycin (drug); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis
Brief Summary: The purpose of this study is to investigate whether treatment against intestinal helminths in patients with pulmonary tuberculosis undergoing chemotherapy could improve the clinical outcome by enhancing host immunity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Drug: Praziquantel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current standard of care in Kenya | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Praziquantel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Current standard of care in Kenya; Assigned to Arm(s): 2
B: Arm Label: Albendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Albendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Arm Label: ivermectin; Type: EXPERIMENTAL; Interventions: Drug: Ivermectin | Arm Label: ivermectin 2 doses; Type: EXPERIMENTAL; Interventions: Drug: ivermectin | Intervention Type: DRUG; Name: Ivermectin; Assigned to Arm(s): ivermectin | Intervention Type: DRUG; Name: ivermectin; Assigned to Arm(s): ivermectin 2 doses | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Brief Summary: A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs); Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)
D: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Arginine Rich Food Supplementation as an Adjuvant Treatment Against Tuberculosis
Brief Summary: The purpose of this study was to investigate if adjuvant treatment with arginine (the substrate for nitric oxide production) rich food supplements could improve clinical outcome in patients with smear positive tuberculosis by affecting nitric oxide production.


Options:
A: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Migliol Placebo Oil; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: multivitamin; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: B. Migliol Oil without Cholecalciferol | Intervention Type: DRUG; Name: A. 100,000 IU Cholecalciferol per dose of 3.3ml; Assigned to Arm(s): A | Intervention Type: OTHER; Name: B. Migliol Oil without Cholecalciferol; Assigned to Arm(s): B
D: Arm Label: Peanuts; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Peanuts | Arm Label: Daboqolo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Daboqolo | Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts; Assigned to Arm(s): Peanuts | Intervention Type: DIETARY_SUPPLEMENT; Name: Daboqolo; Assigned to Arm(s): Daboqolo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Better Breast and Cervical Cancer Control for Korean American Women
Brief Summary: The long-term goal of this study is to build a sustainable,community-based outreach program using Korean American community health workers (CHWs) to promote breast and cervical screening among Korean American women, thereby reducing related morbidity and mortality. The study is designed to determine the effectiveness of a health literacy-focused tailored breast and cervical cancer control intervention delivered by CHWs.

The investigators hypothesized that, compared to KA women in the delayed intervention group, KA women who receive a health literacy-focused CHW intervention will demonstrate: (1) higher levels of adherence to screening for breast and cervical cancer, (2) greater levels of health literacy, (3) higher levels of breast and cervical cancer knowledge, and (4) improve decisional balance.


Options:
A: Arm Label: Senior meetings; Type: EXPERIMENTAL; Interventions: Behavioral: Senior meetings | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Senior meetings; Assigned to Arm(s): Senior meetings
B: Arm Label: ESL Health Literacy Classes; Type: OTHER; Interventions: Behavioral: ESL Health Literacy Classes | Intervention Type: BEHAVIORAL; Name: ESL Health Literacy Classes; Assigned to Arm(s): ESL Health Literacy Classes
C: Arm Label: Health Literacy; Type: EXPERIMENTAL; Interventions: Behavioral: Health literacy, health message | Intervention Type: BEHAVIORAL; Name: Health literacy, health message; Assigned to Arm(s): Health Literacy
D: Arm Label: User intervention; Type: OTHER; Interventions: Behavioral: User intervention | Arm Label: Health professional intervention; Type: OTHER; Interventions: Behavioral: Health professional intervention | Intervention Type: BEHAVIORAL; Name: User intervention; Assigned to Arm(s): User intervention | Intervention Type: BEHAVIORAL; Name: Health professional intervention; Assigned to Arm(s): Health professional intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type
Brief Summary: The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.


Options:
A: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
B: Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)
Brief Summary: This study involves Rheumatoid Arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is intended to identify parameters that can serve as guidance in clinical settings. This study will consider the clinical and radiographic course in subjects when etanercept treatment is tapered or discontinued, and analyze the subjects' experience of disease worsening and the predictive values of clinical parameters, serum biomarkers and imaging on the clinical and radiographic course in different treatment groups. The effect of re-treatment with etanercept at treatment failure will also be studied.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
B: Arm Label: Adalimumab + MTX; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: methotrexate | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab + MTX | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Adalimumab + MTX, Methotrexate
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: CZP 200 mg Q2W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: CZP 200 mg Q4W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo + Methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol + Methotrexate (MTX); Assigned to Arm(s): CZP 200 mg Q2W + Methotrexate, CZP 200 mg Q4W + Methotrexate | Intervention Type: BIOLOGICAL; Name: Placebo + Methotrexate (MTX); Assigned to Arm(s): Placebo + Methotrexate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis.
Brief Summary: Despite recent advances in interventional cardiology including the success of drug-eluting stents in de-novo coronary lesions, the treatment of in-stent restenosis remains a challenging clinical issue. Given the efficacy of the systemic sirolimus administration to prevent neointimal hyperplasia in animal models and to halt and even reverse the progression of allograft vasculopathy, the aim of the present double-blind, placebo-controlled study was to evaluate the efficacy of a 10-day oral sirolimus treatment with two different loading regimens for the prevention of recurrent restenosis in patients with in-stent restenosis.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo
B: Arm Label: Doxycycline; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current medical therapy for AMI | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Current medical therapy for AMI; Assigned to Arm(s): Standard Therapy
C: Arm Label: erythromycin group; Type: N/A; Interventions: N/A | Arm Label: control group; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients Treated With Radiotherapy.
Brief Summary: The purpose of this study is to evaluate the effectiveness and feasibility of the Screening Inventory of Psychosocial Problems (SIPP) in consultation settings with respect to early recognition and treatment of psychosocial distress, communication between patients and physicians, and psychological distress and quality of life in cancer patients treated with radiotherapy (RT).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meaning Centered Group Psychotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Group Psychotherapy | Intervention Type: BEHAVIORAL; Name: Meaning Centered Group Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Group Psychotherapy; Assigned to Arm(s): 2
B: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care
C: Arm Label: Intervention group 1; Type: EXPERIMENTAL; Interventions: Other: Questionnaire administration | Arm Label: Intervention group 2; Type: EXPERIMENTAL; Interventions: Other: Questionnaire administration | Arm Label: Control group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control group 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Questionnaire administration; Assigned to Arm(s): Intervention group 1, Intervention group 2
D: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Smoking Cessation in Heavy Drinking Smokers
Brief Summary: The purpose of this study is to determine whether extended pretreatment with varenicline (Chantix) is more efficacious for smoking cessation than standard pretreatment, how well varenicline is tolerated in heavy drinking smokers, and whether varenicline reduces alcohol consumption.


Options:
A: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
C: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
D: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Smoking Cessation in Heavy Drinking Smokers
Brief Summary: The purpose of this study is to determine whether extended pretreatment with varenicline (Chantix) is more efficacious for smoking cessation than standard pretreatment, how well varenicline is tolerated in heavy drinking smokers, and whether varenicline reduces alcohol consumption.


Options:
A: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: A